康恩貝(600572.SH):子公司乙酰半胱氨酸溶液獲美國FDA批準
格隆匯3月20日丨康恩貝(600572.SH)公佈,全資子公司浙江金華康恩貝生物製藥有限公司(簡稱“金華康恩貝”)在美國設立的全資子公司ConbaUSAInc(簡稱“美國康恩貝”)收到美國食品藥品監督管理局(簡稱“FDA”)的通知,美國康恩貝向FDA申報的的乙酰半胱氨酸溶液新藥簡略申請(ANDA,即美國仿製藥申請)獲得批準。乙酰半胱氨酸,作爲粘液溶解劑,用於治療濃稠粘液分泌物過多的呼吸道疾病,如急性支氣管炎、慢性支氣管炎及其病情惡化者、肺氣腫、粘稠物阻塞症以及支氣管擴張症。在特殊情況下,該藥物也可用於化解過量服用對乙酰氨基酚引發的中毒反應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.